Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report

Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation. We present a patient with recurrent, metastatic,...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology research and practice 2017-02, Vol.4 (1), p.3, Article 3
Main Authors: Paraghamian, Sarah E, Longoria, Teresa C, Eskander, Ramez N
Format: Article
Language:English
Subjects:
Antigens
Cancer therapies
Case Report
Case studies
Cervical cancer
Cervix uteri
Chemotherapy
Consent
Cytokines
Diagnosis
Disease
Dosage and administration
Drug therapy
Gynecology
Health aspects
Human papillomavirus
Immune system
Lung cancer
Medical imaging
Metastasis
Nivolumab
Obstetrics
Patients
Radiation therapy
Small cell carcinoma
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation. We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of disease. Immune checkpoint inhibitors may be active in neuroendocrine cervical cancer, with potential for dramatic responses in a modest subset of patients.
ISSN:2053-6844
2053-6844
DOI:10.1186/s40661-017-0038-9